Cytochrome c: Using Biological Insight toward Engineering an Optimized Anticancer Biodrug
Authors:
- Louis J. DelinoisLDLouis J. Delinois
- Omar De León-VélezOLOmar De León-Vélez
- Adriana Vázquez-MedinaAVAdriana Vázquez-Medina
- Alondra Vélez-CabreraAVAlondra Vélez-Cabrera
- Amanda Marrero-SánchezAMAmanda Marrero-Sánchez
- Christopher Nieves-EscobarCNChristopher Nieves-Escobar
- Daniela Alfonso-CanoDADaniela Alfonso-Cano
- Delvin Caraballo-RodríguezDCDelvin Caraballo-Rodríguez
- Jael Rodriguez-OrtizJRJael Rodriguez-Ortiz
- Jemily Acosta-MercadoJAJemily Acosta-Mercado
- Josué A. Benjamín-RiveraJosué A. Benjamín-Rivera
- Kiara González-GonzálezKGKiara González-González
Open Access
- 16 November 2021
- journal article
- review article
- Published by MDPI AG in Inorganics
- Vol. 9 (11) , 83
Abstract
The heme protein cytochrome c (Cyt c) plays pivotal roles in cellular life and death processes. In the respiratory chain of mitochondria, it serves as an electron transfer protein, contributing to the proliferation of healthy cells. In the cell cytoplasm, it activates intrinsic apoptosis to terminate damaged cells. Insight into these mechanisms and the associated physicochemical properties and biomolecular interactions of Cyt c informs on the anticancer therapeutic potential of the protein, especially in its ability to subvert the current limitations of small molecule-based chemotherapy. In this review, we explore the development of Cyt c as an anticancer drug by identifying cancer types that would be receptive to the cytotoxicity of the protein and factors that can be finetuned to enhance its apoptotic potency. To this end, some information is obtained by characterizing known drugs that operate, in part, by triggering Cyt c induced apoptosis. The application of different smart drug delivery systems is surveyed to highlight important features for maintaining Cyt c stability and activity and improving its specificity for cancer cells and high drug payload release while recognizing the continuing limitations. This work serves to elucidate on the optimization of the strategies to translate Cyt c to the clinical market.Keywords
Funding Information
- NIH (1R21CA240997-01A1)
- NIH RISE (5R25GM061151)
- NIH MARC (5T34GM007821-40S1)
- NSF CAWT (OIA-1849243)
- NSF DMR (1523463)
- NSF REU (1757365)
- University of Puerto Rico Rio Piedras (FIPI)
This publication has 117 references indexed in Scilit:
- Cell survival, DNA damage, and oncogenic transformation after a transient and reversible apoptotic responseMolecular Biology of the Cell, 2012
- Cancer cell–selective in vivo near infrared photoimmunotherapy targeting specific membrane moleculesNature Medicine, 2011
- The role of oxidized cytochrome c in regulating mitochondrial reactive oxygen species production and its perturbation in ischaemiaBiochemical Journal, 2011
- The multiple functions of cytochrome c and their regulation in life and death decisions of the mammalian cell: From respiration to apoptosisMitochondrion, 2011
- CytochromecBiogenesis: Mechanisms for Covalent Modifications and Trafficking of Heme and for Heme-Iron Redox ControlMicrobiology and Molecular Biology Reviews, 2009
- The BCL-2 protein family: opposing activities that mediate cell deathNature Reviews Molecular Cell Biology, 2008
- How Cytochrome c Folds, and Why: Submolecular Foldon Units and their Stepwise Sequential StabilizationJournal of Molecular Biology, 2004
- Stability and apoptotic activity of recombinant human cytochrome cBiochemical and Biophysical Research Communications, 2003
- Lonidamine triggers apoptosis via a direct, Bcl-2-inhibited effect on the mitochondrial permeability transition poreOncogene, 1999
- Intramolecular Electron Transfer in Pentaammineruthenium(III)-Modified Cobaltocytochrome cInorganic Chemistry, 1996